CERE News and Press, Ceres Inc. From 03/10/24

2024-03-10 12:23:46 ET Summary AbbVie's full-year results for 2023 might have been weak, but its price is still up by 15% YTD. The disconnect is explained by the revenue dip because of patent expiration for its blockbuster drug Humira, though revenues-ex Humira saw healthy growth....

2024-03-08 15:00:00 ET More on the markets S&P 500: Time To Hedge, Here's How How The S&P 500 Could Actually Be Closer To 4,200 Than 5,000 SPDR S&P 500 ETF And Invesco QQQ Trust: Almost All Investors Are Crowded Into The Same Side Of The Boat ETFs...

2024-03-06 07:20:44 ET Summary The FTC is requesting more information on the merger between Cerevel Therapeutics and AbbVie. Concerns may be focused on the Phase 3 treatment Tavapadon for Parkinson's disease. The market expects a 75% chance of the acquisition going through, wh...

Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...

SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...

2024-02-21 13:26:32 ET More on AbbVie AbbVie Q4: Now Isn't The Time To Buy My Largest Big Pharma Holding AbbVie: Game Changer AbbVie Q4 Review: Stock Remains A Buy, Encouraged By Skyrizi And Rinvoq AbbVie names Robert A. Michael as CEO and Richard A. Gonzalez...

2024-02-18 10:22:04 ET Summary Karuna Therapeutics is developing a novel product, KarXT, to treat psychoses related to Alzheimer's and schizophrenia. The product targets muscarinic receptors in an agonist/antagonist combination. Some shareholders are suing to prevent the acqui...

2024-02-16 17:56:00 ET More on AbbVie, Cerevel Therapeutics, etc. AbbVie Q4: Now Isn't The Time To Buy My Largest Big Pharma Holding AbbVie: Game Changer AbbVie Q4 Review: Stock Remains A Buy, Encouraged By Skyrizi And Rinvoq Dividend Roundup: Target, Meta Pl...

2024-02-12 08:14:34 ET AbbVie ( NYSE: ABBV ) has updated its earnings outlook for the first quarter of 2024 to reflect a dilutive impact related to its acquisition of cancer drugmaker ImmunoGen ( NASDAQ: IMGN ).... Read the full article on Seeking Alpha For f...

2024-02-10 20:30:24 ET Summary Neurocrine Biosciences' shares have sold off post-earnings on concerns about its near-term opex spending and slowing growth for lead drug Ingrezza. Higher-than-expected opex spending includes targeted spending to grow the Ingrezza business (Huntingto...